TY - JOUR
T1 - Early Ventricular Arrhythmias After Left Ventricular Assist Device Implantation
AU - Oates, Connor P.
AU - Lam, Phillip H.
AU - Lawrence, Luke
AU - Bigham, Grace
AU - Meda, Namratha S.
AU - Basyal, Binaya
AU - Hadadi, Cyrus A.
AU - Rao, Sriram D.
AU - Hockstein, Michael
AU - Shah, Manish
AU - Sheikh, Farooq H.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2024/8
Y1 - 2024/8
N2 - Background: Although sustained ventricular arrhythmias (VAs) are a common complication after durable left ventricular assist device (LVAD) implantation, the incidence, risk factors, and prognostic implications of postoperative early VAs (EVAs) in contemporary patients with LVAD are poorly understood. Methods and Results: A single-center retrospective analysis was performed of patients who underwent LVAD implantation from October 1, 2006, to October 1, 2022. EVA was defined as an episode of sustained VA identified ≤30 days after LVAD implantation. A total of 789 patients underwent LVAD implantation (mean age 62.9 ± 0. years 5, HeartMate 3 41.4%, destination therapy 43.3%). EVAs occurred in 100 patients (12.7%). A history of end-stage renal disease (odds ratio [OR] 5.6, 95% confidence interval [CI] 1.45–21.70), preoperative electrical storm (OR 2.82, 95% CI 1.11–7.16), and appropriate implantable cardiac defibrillator therapy before implantation (OR 2.8, 95% CI 1.26–6.19) are independently associated with EVAs. EVA was associated with decreased 30-day survival (hazard ratio 3.02, 95% CI 1.1–8.3, P = .032). There was no difference in transplant-free survival time between patients with and without EVAs (hazard ratio 0.82, 95% CI 0.5–1.4, P = .454). Conclusions: EVAs are common after durable LVAD implantation and are associated with an increased risk of 30-day mortality.
AB - Background: Although sustained ventricular arrhythmias (VAs) are a common complication after durable left ventricular assist device (LVAD) implantation, the incidence, risk factors, and prognostic implications of postoperative early VAs (EVAs) in contemporary patients with LVAD are poorly understood. Methods and Results: A single-center retrospective analysis was performed of patients who underwent LVAD implantation from October 1, 2006, to October 1, 2022. EVA was defined as an episode of sustained VA identified ≤30 days after LVAD implantation. A total of 789 patients underwent LVAD implantation (mean age 62.9 ± 0. years 5, HeartMate 3 41.4%, destination therapy 43.3%). EVAs occurred in 100 patients (12.7%). A history of end-stage renal disease (odds ratio [OR] 5.6, 95% confidence interval [CI] 1.45–21.70), preoperative electrical storm (OR 2.82, 95% CI 1.11–7.16), and appropriate implantable cardiac defibrillator therapy before implantation (OR 2.8, 95% CI 1.26–6.19) are independently associated with EVAs. EVA was associated with decreased 30-day survival (hazard ratio 3.02, 95% CI 1.1–8.3, P = .032). There was no difference in transplant-free survival time between patients with and without EVAs (hazard ratio 0.82, 95% CI 0.5–1.4, P = .454). Conclusions: EVAs are common after durable LVAD implantation and are associated with an increased risk of 30-day mortality.
KW - Ventricular tachycardia
KW - left ventricular assist device
KW - ventricular fibrillation
UR - https://www.scopus.com/pages/publications/85182352411
U2 - 10.1016/j.cardfail.2023.11.018
DO - 10.1016/j.cardfail.2023.11.018
M3 - Article
C2 - 38103723
AN - SCOPUS:85182352411
SN - 1071-9164
VL - 30
SP - 1018
EP - 1027
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 8
ER -